Literature DB >> 323119

Immunoprophylaxis and therapy of grafted rat colonic carcinoma.

M S Martin, F Martin, E Justrabo, M F Michel, A Lagneau.   

Abstract

Two independent lines of chemically-induced colonic carcinoma, serially graftable in syngeneic rats, have been used to investigate the effects of immunoprophylaxis and immunotherapy. Rats were immunised by various procedures, including BCG, irradiated tumour grafts, and cancer cells treated by mitomycin and neuraminidase. A partial inhibition of tumour growth was observed in one of the four protocols. On the other hand, a significant enhancement of tumour growth was obtained in two other experiments.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 323119      PMCID： PMC1411394          DOI： 10.1136/gut.18.3.232

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  19 in total

1.  BCG immunotherapy of rat tumors of defined immunogenicity.

Authors:  R W Baldwin; M V Pimm
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

2.  Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy.

Authors:  R L Simmons; A Rios
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

3.  Cross-reacting tumor-associated antigen (s) among chemically induced rat colon carcinomas.

Authors:  G Steele; H O Sjögren
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

4.  Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

Authors:  G L Bartlett; B Zbar
Journal:  J Natl Cancer Inst       Date:  1972-06       Impact factor: 13.506

5.  Skin-reactive soluble antigen from intestinal cancer-cell-membranes and relationship to carcinoembryonic antigens.

Authors:  A Hollinshead; D Glew; B Bunnag; P Gold; R Herberman
Journal:  Lancet       Date:  1970-06-06       Impact factor: 79.321

6.  Tumour-specific antigenicity of aminoazo-dye-induced rat hepatomas.

Authors:  R W Baldwin; C R Barker
Journal:  Int J Cancer       Date:  1967-07-15       Impact factor: 7.396

7.  Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guérin and neuraminidase.

Authors:  F C Sparks; J H Breeding
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

8.  Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.

Authors:  C G Moertel; R E Ritts; A J Schutt; R G Hahn
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

9.  Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil.

Authors:  G M Mavligit; J U Gutterman; M A Burgess; N Khankhanian; G B Seibert; J F Speer; A V Jubert; R C Martin; C M McBride; E M Copeland; E A Gehan; E M Hersh
Journal:  Lancet       Date:  1976-04-24       Impact factor: 79.321

10.  Circulating antibodies in rats bearing grafted colon carcinoma.

Authors:  F Martin; M Martin; A Lagneau; M Bordes; S Knobel
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.